Recent headlines about marijuana rescheduling have sparked confusion across industries, especially for employers, Medical Review Officers (MROs), and supervisors responsible for maintaining safe, drug-free workplaces.
On April 23, 2026, the U.S. Department of Justice and the Drug Enforcement Administration issued an order placing certain marijuana-related products into Schedule III and initiating a formal rulemaking process to consider broader rescheduling. While this development is significant from a policy standpoint, it does not change workplace drug testing requirements at this time.
📥 New Resource: Quick Guidance for Employers, MROs, and Supervisors
To help cut through the confusion, we’ve developed a practical, easy-to-use guide: “April 2026 DOJ/DEA Marijuana Order: What Employers, MROs, and Supervisors Need to Know.”
✔ One-page breakdown of what changed and what didn’t
✔ Clear guidance for workplace drug testing and compliance
✔ Actionable takeaways for employers, MROs, and supervisors
👉 Download the resource here to ensure your workplace policies remain compliant and informed.
Cutting Through the Confusion
There is a growing narrative that rescheduling marijuana automatically changes workplace policies or makes marijuana use acceptable in safety-sensitive roles. That is not the case.
As outlined in our new resource:
- Federal drug testing programs remain unchanged
- Marijuana is still treated as a Schedule I substance for workplace testing purposes
- Medical marijuana is not an acceptable explanation for a positive THC test under federal regulations
For employees in safety-sensitive positions, such as those regulated by the U.S. Department of Transportation or other federal agencies, marijuana use remains prohibited, regardless of state laws or medical claims.
What This Means for Employers and MROs
For now, the guidance is straightforward:
- Continue enforcing existing drug-free workplace policies
- Do not reinterpret or downgrade THC-positive test results
- Ensure policies clearly address marijuana use, including medical use
- Maintain training for supervisors on impairment recognition and reasonable suspicion
MRO responsibilities also remain consistent. Verification processes and reporting protocols should not change based on this order alone.
A Process—Not a Policy Change
It’s important to understand that this DOJ/DEA action is part of an ongoing administrative process, not an immediate regulatory shift.
A formal hearing is scheduled to begin June 29, 2026, and future changes could include:
- Updates to federal drug testing frameworks
- New guidance for safety-sensitive roles
- Legislative or regulatory adjustments
However, these outcomes are not yet in effect, and legal challenges could further delay any changes.
Critical Takeaways
Rescheduling discussions may shape the future—but they do not change today’s expectations.
Workplace drug testing standards remain intact.
MRO practices remain unchanged.
Employer responsibility remains critical.
As the policy landscape evolves, employers and prevention professionals should stay informed, but avoid making premature changes that could compromise safety, compliance, or clarity.
👉 Download the Workplace Guidance on the April 2026 DOJ/DEA Marijuana Order
